Abbisko Cayman Limited (2256) Price & Analysis

Compare

6 Followers

2256 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$2.85 - HK$17.50

Previous CloseN/A

Volume927.00K

Average Volume (3M)6.12M

Market Cap

HK$11.44B

Enterprise ValueHK$4.11B

Total Cash (Recent Filing)HK$1.96B

Total Debt (Recent Filing)HK$24.29M

Price to Earnings (P/E)60.1

Beta1.34

Next Earnings

Mar 12, 2026

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.56

Shares Outstanding680,105,350

10 Day Avg. Volume7,991,198

30 Day Avg. Volume6,121,207

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$18.00

Price Target Upside7.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe preliminary data for a subset of patients treated with pimicotinib 20 mg QD demonstrated a 64% overall response rate with responses observed in all affected organs.

Pipeline DevelopmentThe company advances oncology pipeline, initiating a registrational study for irpagratinib in hepatocellular carcinoma.

Regulatory ProgressThe company announced acceptance of the pimicotinib NDA in China for Tenosynovial Giant Cell Tumor, with an expedited review and Merck KGaA opted-in to commercialize pimicotinib in the US/EU.

Bears Say

Drug Development RisksThe company highlighted the latest dataset for pimicotinib in Chronic Graft-versus-Host Disease patients who either progressed or did not respond to at least one prior line of therapy.

Regulatory ChallengesThe company expects to submit an NDA for pimicotinib in Tenosynovial Giant Cell Tumor to the Chinese NMPDA and to the US FDA, demonstrating best-in-class efficacy in TGCT.

Abbisko Cayman Limited News

Abbisko’s PD-L1 Inhibitor ABSK043 Gains IND Clearance for NSCLC Treatment

Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an announcement. Abbisko Cayman Limited announced that its subsidiary, Abbisko...

5d ago

2256

Abbisko’s Strategic Advancements and Promising Pipeline Drive Buy Rating

Abbisko Cayman Limited, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Berens...

19d ago

Abbisko Cayman Limited Reports Key Milestones in Drug Development for H1 2025

Abbisko Cayman Limited ( ($HK:2256) ) has shared an update. Abbisko Cayman Limited has announced significant advancements in...

21d ago

2256

Abbisko Cayman Limited Enhances Governance with New Nomination Committee

An update from Abbisko Cayman Limited ( ($HK:2256) ) is now available. Abbisko Cayman Limited has established a...

21d ago

2256

Abbisko Therapeutics Initiates Phase 1 Trial for Innovative Cancer Drug ABSK131

Abbisko Cayman Limited ( ($HK:2256) ) has provided an announcement. Abbisko Cayman Limited announced that its subsidiary, Abbisko...

1M ago

2256

Abbisko Cayman Limited Schedules Board Meeting for Interim Results

Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an announcement. Abbisko Cayman Limited has announced an upcoming board...

1M ago

2256

Abbisko Therapeutics to Present Promising Phase 2 Study Results at ESMO GI Congress

The latest announcement is out from Abbisko Cayman Limited ( ($HK:2256) ). Abbisko Therapeutics announced that it will...

2M ago

2256

Abbisko Therapeutics Advances Achondroplasia Study with First Patient Enrollment

Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an update. Abbisko Cayman Limited announced that its subsidiary, Abbisko...

2M ago

2256

Abbisko Cayman Limited AGM Resolutions Passed

An announcement from Abbisko Cayman Limited ( ($HK:2256) ) is now available. Abbisko Cayman Limited announced that all...

2M ago

2256

Abbisko Therapeutics Advances HCC Treatment with Irpagratinib Study

Abbisko Cayman Limited ( ($HK:2256) ) has shared an update. Abbisko Cayman Limited announced that its subsidiary, Abbisko...

2M ago

2256

2256 FAQ

What was Abbisko Cayman Limited’s price range in the past 12 months?

Abbisko Cayman Limited lowest stock price was HK$2.85 and its highest was HK$17.50 in the past 12 months.

What is Abbisko Cayman Limited’s market cap?

Abbisko Cayman Limited’s market cap is HK$11.44B.

When is Abbisko Cayman Limited’s upcoming earnings report date?

Abbisko Cayman Limited’s upcoming earnings report date is Mar 12, 2026 which is in 199 days.

How were Abbisko Cayman Limited’s earnings last quarter?

Abbisko Cayman Limited released its earnings results on Aug 04, 2025. The company reported HK$0.556 earnings per share for the quarter, the consensus estimate of HK$0.556 by HK$0.

Is Abbisko Cayman Limited overvalued?

According to Wall Street analysts Abbisko Cayman Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abbisko Cayman Limited pay dividends?

Abbisko Cayman Limited does not currently pay dividends.

What is Abbisko Cayman Limited’s EPS estimate?

Abbisko Cayman Limited’s EPS estimate is -0.41.

How many shares outstanding does Abbisko Cayman Limited have?

Abbisko Cayman Limited has 680,105,350 shares outstanding.

What happened to Abbisko Cayman Limited’s price movement after its last earnings report?

Abbisko Cayman Limited reported an EPS of HK$0.556 in its last earnings report, expectations of HK$0.556. Following the earnings report the stock price went up 2.854%.

Which hedge fund is a major shareholder of Abbisko Cayman Limited?

Currently, no hedge funds are holding shares in HK:2256

Abbisko Cayman Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

6.73%

Trailing 12-Months

Asset Growth

10.17%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abbisko Cayman Limited

Abbisko Cayman Limited (2256) is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and other diseases. The company operates primarily in the healthcare and biotechnology sectors, specializing in creating small molecule drugs aimed at addressing unmet medical needs. Abbisko's core products include a pipeline of proprietary drug candidates that target a variety of oncological and other disease indications.

Abbisko Cayman Limited (2256) Earnings & Revenues

Historic Earnings Reports

2256 Stock 12 Month Forecast

Average Price Target

HK$18.00

▲(7.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","10":"HK$10","19":"HK$19","5.5":"HK$5.5","14.5":"HK$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.5,10,14.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Mar<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.16,10.763076923076923,11.366153846153846,11.96923076923077,12.572307692307692,13.175384615384615,13.778461538461539,14.381538461538462,14.984615384615385,15.587692307692308,16.19076923076923,16.793846153846154,17.396923076923077,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.16,10.763076923076923,11.366153846153846,11.96923076923077,12.572307692307692,13.175384615384615,13.778461538461539,14.381538461538462,14.984615384615385,15.587692307692308,16.19076923076923,16.793846153846154,17.396923076923077,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.16,10.763076923076923,11.366153846153846,11.96923076923077,12.572307692307692,13.175384615384615,13.778461538461539,14.381538461538462,14.984615384615385,15.587692307692308,16.19076923076923,16.793846153846154,17.396923076923077,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.67,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.9,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.26,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.61,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.34,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.66,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.66,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >